Trending News

Blog Post


Gilead to cease late-stage research of Covid-19 therapy 

A scientist at Gilead Sciences analyzes affected person antibody ranges on the Gilead laboratory in Foster Metropolis, California.

David Paul Morris | Bloomberg | Getty Photographs

Gilead Sciences mentioned on Monday it had determined to cease a late-stage trial of its intravenous therapy, Veklury, in high-risk non-hospitalized sufferers with Covid-19.

The corporate mentioned it not believes that growing a multiple-day injection that requires administration in a healthcare setting addresses an unmet want for non-hospitalized sufferers.

The choice to cease the research shouldn’t be as a consequence of efficacy or security considerations, Gilead mentioned.

Supply hyperlink

Related posts

Leave a Reply

Required fields are marked *